Opthea Limited Sponsored ADR (OPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

MELBOURNE, Australia and PRINCETON, N.J. - Opthea Limited (ASX/NASDAQ: OPT), a biopharmaceutical company focused on developing treatments for retinal diseases, has published the results of its ...

MELBOURNE, Australia and PRINCETON, N.J. - Opthea Limited (ASX/NASDAQ: OPT), a biopharmaceutical company focused on developing treatments for retinal diseases, has published the results of its Phase ...

Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases ...

Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent ...

Opthea Limited (ASX/NASDAQ: OPT "Opthea”, the "Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...